Navigation Links
MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results

Company prepares to launch Moxatag(TM), the first and only FDA-approved

once-daily amoxicillin, in the first quarter of 2009
GERMANTOWN, Md., Nov. 13 /PRNewswire-FirstCall/ --


-- MiddleBrook Pharmaceuticals received stockholder approval for and

closed a $100 million financing transaction with Equity Group

Investments, L.L.C. (EGI). (Sept.)

-- MiddleBrook repurchased the Keflex(R) assets for approximately $11.0

million from Deerfield Management and redeemed the Deerfield warrant

for $8.8 million in conjunction with the EGI transaction. (Sept.)

-- John Thievon became president & CEO, and David Becker became executive

vice president & CFO effective upon the close of the EGI transaction.


-- The MiddleBrook team was expanded to include additional senior leaders

with proven track records in commercial operations. (Sept. - Nov.)

-- MiddleBrook engaged TalenTactics(TM) to lead its national sales force

hiring efforts and teamed with VCG & Associates to obtain managed-care

coverage for Moxatag (extended-release amoxicillin) Tablets, 775mg.


-- The Company's Moxatag patents were listed in FDA's Orange Book. (Oct.)

-- MiddleBrook President & CEO John Thievon presented at the 10th Annual

Rodman & Renshaw Healthcare Conference. (Nov.)

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced financial and operational results for the quarter ended Sept. 30, 2008.

MiddleBrook President & CEO John Thievon said, "We have made significant progress since September. We have expanded the MiddleBrook senior leadership team, and our accomplished science team is now complemented with operationally strong executives, many of whom have a shared history of commercial success."

"We will begin recruiting our national field force shortly, and the entire MiddleBrook team is energized and focused on the execution of our plan to successfully launch our first proprietary Pulsys(R) product, Moxatag -- the first and only FDA-approved once-daily amoxicillin -- in first quarter 2009," Thievon continued.

Third Quarter 2008 Financial Results:

MiddleBrook reported third quarter 2008 revenue of $2.3 million, compared to revenue of $3.1 million in the third quarter of 2007. The lower revenue is due primarily to the fact that during 2007 MiddleBrook reduced the size of its contract sales force from 75 to 30 representatives in order to lower expenses.

The Company reported cost of goods sold in the amount of $0.3 million, compared to $1.2 million in the prior year period. The decline is due primarily to the third quarter 2007 write-off of obsolete immediate-release Keflex (cephalexin USP) capsules inventory.

Research and development (R&D) expenses in the third quarter were $6.9 million, compared to third quarter 2007 R&D expenses of $5.5 million. Third quarter 2008 R&D expenses include a loss on R&D equipment sold during the quarter of $1.0 million and a $3.1 million impairment of leasehold improvements related to currently unused leased space which the Company plans to sublease. In 2007, R&D headcount was reduced and all development activities outside of those related to Moxatag were put on hold. These actions partially offset the expense associated with the loss and the impairment.

Selling, general and administrative (SG&A) expense was $7.0 million in the third quarter of 2008, compared to $6.5 million in the prior-year period. Third quarter 2008 SG&A expense includes $2.1 million in severance expense associated with management changes related to the EGI transaction. The severance expense more than offset savings generated from lower headcount, including the reduced contract sales force and the other cost reduction efforts.

Net loss was $(12.5) million for the third quarter, compared to a net loss of $(10.1) million in the third quarter of 2007. Net loss per share during the third quarter of 2008 was $(0.19), compared to a net loss per share of $(0.22) in the prior- year quarter. The number of shares used in the per share calculation was 64.6 million for the current quarter and includes the weighted average impact of the 30.3 million new shares purchased by EGI in Sept. 2008.


MiddleBrook now expects 2008 net sales to be approximately $9.0 million as a result of declining Keflex prescriptions due to the lower number of physician detail calls made as a result of the reduction in the size of the Company's contract sales force. At the end of 2008, MiddleBrook anticipates that it will have combined cash and marketable securities balance in excess of $70 million. Cash utilization during the fourth quarter 2008 is expected to increase as a result of the new sales infrastructure and the purchase of the initial Moxatag inventory for the upcoming launch.

MiddleBrook's current plan anticipates that 2009 net sales will be in excess of $40 million for Moxatag and Keflex combined, assuming the successful commercial launch of Moxatag in the first quarter of 2009 and no generic competition for Keflex 750mg.

As part of MiddleBrook's current 2009 plan, MiddleBrook will build a field force consisting of about 270 professional field sales representatives at a fully-burdened annual cost of approximately $190 thousand per sales representative.

MiddleBrook's current 2009 plan indicates that the Company expects to advance the Keflex Pulsys development project, contingent upon the success of the Moxatag launch. Additionally, the current MiddleBrook 2010 plan supports the potential for achieving operating profitability without the need for additional equity financing.

Third Quarter 2008 Conference Call and Webcast

MiddleBrook Pharmaceuticals, Inc. is scheduled to announce its financial results for the third quarter of 2008 today, Thursday, Nov. 13, 2008, before the market opens. At 9:00 a.m. (ET) today, MiddleBrook management will conduct a conference call to review the Company's third quarter financial results.

To listen live to the call, dial 1-800-813-8504 or 1-706-643-7752. A replay of the call will be available starting at approximately 11 a.m. on Nov. 13 through 5 p.m. on Nov. 20, 2008. To listen to the replay, dial 1-800-642- 1687 or 1-706-645-9291 and enter the conference ID # 71538195.

A live audio webcast of the conference call also will be available by going to the Investor Relations section of MiddleBrook's web site, A replay of the webcast will be available starting at approximately 11 a.m. on Nov. 13 through 5 p.m. on Dec. 12, 2008.

About Moxatag:

Moxatag (amoxicillin extended-release) Tablets, 775mg, is a once-a-day extended-release formulation of amoxicillin for oral administration consisting of three components: one immediate-release component and two delayed-release components. The three components of Moxatag are combined in a specific ratio to prolong the release of amoxicillin compared to immediate-release amoxicillin. Moxatag is intended to provide a lower treatment dose, once- daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and older with tonsillitis and/or pharyngitis. For more information about Moxatag, please visit

About Keflex:

Keflex, immediate-release (cephalexin USP) capsules, is a first-generation cephalosporin antibiotic shown to be active against strains of both gram- positive and gram- negative aerobes in vitro and in clinical infections. Keflex is indicated for treatment of the following infections: respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections. More information on Keflex and prescribing information are available at

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs. We are currently developing a portfolio of anti- infective products utilizing our proprietary, once-a-day pulsatile delivery technology called Pulsys. Our near-term corporate strategy is to improve dosing regimens and/or frequency of dosing which we believe will result in improved patient dosing convenience and compliance for antibiotics that have been used and trusted by physicians and patients for decades. The Company currently markets the Keflex brand of cephalexin and has received regulatory approval for Moxatag -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more information about MiddleBrook, please visit

Forward-Looking Statements

This announcement contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, that involve risks and uncertainties. In some cases, forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "potential," "estimate," "will," "may," "predict," "should," "could," "would" and similar expressions. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this announcement. All of these forward-looking statements are based on information available to us at this time. Actual results could differ from those projected in these forward-looking statements as a result of many factors, including those identified in the sections titled "Risk Factors," in our Registration Statement on Form S-3 as filed with the Securities and Exchange Commission on October 17, 2008, and in our "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in our Annual Report on Form 10-K for the year ended Dec. 31, 2007 and in similar disclosures made by us from time to time in our other filings with the Securities and Exchange Commission. We undertake no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission. MiddleBrook, MiddleBrook Pharmaceuticals (stylized), MiddleBrook Pharmaceuticals, Inc., Pulsys, Moxatag and Keflex are our trademarks and have been registered in the U.S. Patent and Trademark Office or are the subject of pending U.S. trademark applications. Each of the other trademarks, tradenames or services marks appearing in this document belongs to its respective holder.

MiddleBrook Pharmaceuticals, Inc.

Consolidated Statements of Income

(Amounts in thousands, except per share amounts)

For the Three Months For the Nine Months

Ended September 30, Ended September 30,

2008 2007 2008 2007

Product sales $2,267 $3,145 $7,183 $7,598

Costs and expenses:

Cost of product sales 350 1,184 1,345 1,865

Research and development 6,898 5,509 14,270 18,485

Selling, general and

administrative 7,004 6,476 15,695 20,474

Total expenses 14,252 13,169 31,310 40,824

Loss from operations (11,985) (10,024) (24,127) (33,226)

Interest income 172 126 387 482

Interest expense - (159) - (529)

Change in fair value

of warrants (954) - (6,714) -

Other income (expense) - - - 75

Loss including

noncontrolling interest (12,767) (10,057) (30,454) (33,198)

Loss (gain) attributable

to noncontrolling

interest 305 - 485 -

Net loss $(12,462) $(10,057) $(29,969) $(33,198)

Basic and diluted net

loss per share

applicable to common

stockholders $(0.19) $(0.22) $(0.52) $(0.78)

Shares used in

calculation of basic

and diluted net loss

per share 64,649 46,651 58,021 42,832

MiddleBrook Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(Amounts in thousands, except per share amounts)

September 30, December 31,

2008 2007


Current assets:

Cash and cash equivalents $74,343 $1,952

Marketable securities 8,927 -

Accounts receivable, net 577 688

Inventories, net 419 688

Prepaid expenses and other current assets 1,565 1,142

Total current assets 85,831 4,470

Property and equipment, net 3,637 10,929

Restricted cash 872 872

Deposits and other assets 426 175

Intangible assets, net 11,691 7,220

Total assets $102,457 $23,666



Current liabilities:

Accounts payable $2,591 $1,660

Accrued expenses 4,945 5,613

Total current liabilities 7,536 7,273

Warrant liability - 2,100

Deferred contract revenue 11,625 11,625

Deferred rent and credit on lease concession 955 1,178

Total liabilities 20,116 22,176

Noncontrolling interest - 7,338

Commitments and contingencies

Stockholders' equity (deficit):

Preferred stock, $0.01 par value; 25,000

shares authorized, no shares issued or

outstanding at September 30, 2008 and

December 31, 2007 - -

Common stock, $0.01 par value; 225,000

shares authorized, and 86,420 and

46,749 shares issued and outstanding at

September 30, 2008 and December 31, 2007,

respectively 864 467

Capital in excess of par value 306,743 189,019

Accumulated deficit (225,303) (195,334)

Accumulated other comprehensive income 37 -

Total stockholders' equity (deficit) 82,341 (5,848)

Total liabilities, noncontrolling

interest and stockholders' equity

(deficit) $102,457 $23,666

MiddleBrook Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(Amounts in thousands, except per share amounts)(unaudited)

Nine Months Ended September 30,

2008 2007

Cash flows from operating activities:

Net loss $(29,969) $(33,198)

Adjustments to reconcile net income to

net cash in operating activities:

Loss attributable to noncontrolling

interest (485) -

Depreciation and amortization 5,850 3,447

Change in fair value of warrants 6,714 -

Stock-based compensation 1,256 1,972

Deferred rent and credit on lease

concession (223) (48)

Amortization of premium on marketable

securities (30) (69)

Loss on disposal of fixed assets 968 -

Changes in:

Accounts receivable 111 (1,029)

Inventories 269 988

Prepaid expenses and other current assets 472 483

Deposits other than on property and

equipment, and other assets (250) 250

Accounts payable 931 706

Accrued expenses (657) (1,975)

Deferred product revenue - (189)

Net cash used in operating activities (15,043) (28,662)

Cash flows from investing activities:

Repurchase of Keflex assets from Deerfield (12,190) -

Purchases of marketable securities (11,240) (5,868)

Sale and maturities of marketable securities 2,380 5,530

Purchases of property and equipment (39) (246)

Deposits on property and equipment - (1,150)

Proceeds from sale of fixed assets 472 -

Net cash used in investing activities (20,617) (1,734)

Cash flows from financing activities:

Proceeds from private placement of common

stock, net of issue costs 115,943 22,412

Payments on lines of credit - (2,000)

Proceeds from exercise of common stock

options 758 115

Proceeds from exercise of common stock

warrants 164 -

Payment to settle warrant liability (8,814) -

Net cash provided by financing

activities 108,051 20,527

Net increase (decrease) in cash and cash

equivalents 72,391 (9,869)

Cash and cash equivalents, beginning of period 1,952 14,857

Cash and cash equivalents, end of period $74,343 $4,988

Supplemental disclosure of cash flow


Cash paid for interest $-- $475

Supplemental disclosure of noncash


Reclassification of liability related to

early exercises of restricted stock to equity

upon vesting of the restricted stock $-- $19

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
3. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
4. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
5. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
6. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
7. MiddleBrook to Webcast Management Presentation at the 10th Annual Rodman & Renshaw Healthcare Conference
8. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
9. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
10. MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
(Date:11/30/2015)... ... 2015 , ... MOSI recently added two state-of-the-art augmented reality (AR) experiences from ... to their collection of interactive exhibits within the Kids In Charge! building. In collaboration ... to get closer than ever to a range of animals as they drink, sleep ...
(Date:11/30/2015)... ... 2015 , ... The world of hair transplants and restoration is filled with ... and procedures have been in use for many years and are among the most ... M.D. has utilized many of these methods over the years, he also keeps an ...
(Date:11/30/2015)... ... 30, 2015 , ... On Saturday, October 24th, 2015, at the Mill Race ... event, a 5K walk known as “Making Strides Against Breast Cancer”. Patients and staff ... also located in Battle Creek, joined in for this campaign that sought to raise ...
(Date:11/30/2015)... ... 2015 , ... The presidential race normally deals with political issues of national ... national news story when Donald Trump makes disparaging remarks about Hillary Clinton’s hairstyle? It ... anyone wants to admit when it comes to how people are viewed by others. ...
(Date:11/30/2015)... , ... November 30, 2015 , ... According to an ... Decker made a brave but slightly unusual choice to show her Instagram followers that ... pre-pregnancy form may have been pre-mature. Saying that she didn’t “want to mislead any ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015 --> --> ... Market by Product (Soft Tissue, All Tissue, Dental Welding Lasers), ... and Geography - Global Forecast to 2020", published by MarketsandMarkets, ... a CAGR of 5.2% during the forecast period from 2015 ... and 62 Figures spread through 167 P ages and ...
(Date:11/30/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ), a clinical-stage ... delivery systems, announced today it has signed definitive licensing ... of Technologies Co., Ltd. ("HTIT") for exclusive rights to ... China , Hong Kong ... signed at the Israel Knesset (Parliament). ...
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
Breaking Medicine Technology: